Haemonetics (HAE) Q3 2026 earnings summary

Executive summary

• Q3 revenue was $339M, down 2.7% year-over-year, with year-to-date revenue at $988M; organic ex-CSL revenue grew 7.5% year-over-year.

• Net income for Q3 was $44.7M, up 19.3% year-over-year; adjusted EPS increased 10% to $1.31.

• Gross margin improved to 59.7% (up 420 bps); adjusted gross margin was 60.2% (up 250 bps).

• Strong performance in Plasma and Blood Management Technologies, with ongoing innovation and portfolio transformation supporting margin expansion.

• Recent acquisitions, including Vivasure Medical, expanded the interventional technologies portfolio; share repurchases continued.

Financial highlights

• Q3 operating income was $67.4M (19.9% margin), up from $59.0M (16.9%) last year; adjusted operating margin was 26.3%.

• Q3 net income margin was 13.2%; adjusted net income margin was 18.1%.

• Free cash flow for Q3 was $74.2M, up 151% year-over-year; free cash flow conversion reached 121%.

• Cash and cash equivalents at quarter-end were $363M, up from $307M sequentially.

• Net leverage ratio improved to 2.37x EBITDA; long-term debt stood at $920M.

Outlook and guidance

• Full-year reported revenue guidance updated to a decline of 1%-3%; organic revenue guidance at 0-2%.

• Organic revenue guidance ex-CSL increased to 8%-10%; Plasma segment organic ex-CSL growth guidance raised to 17–19%.

• Adjusted EPS guidance for FY26 raised to $4.90–$5.00.

• Free cash flow guidance increased to $200–$220M, with conversion expected to exceed 80%.

• Hospital business expected to deliver ~4% growth at the low end of prior range.